Christian Klein
Christian Klein
Roche Pharma Research and Early Development, Roche Innovation Center Zurich
Verified email at
Cited by
Cited by
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev, BT Vu, B Graves, D Carvajal, F Podlaski, Z Filipovic, N Kong, ...
Science 303 (5659), 844-848, 2004
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell …
E Mössner, P Brünker, S Moser, U Püntener, C Schmidt, S Herter, R Grau, ...
Blood, The Journal of the American Society of Hematology 115 (22), 4393-4402, 2010
A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
DS Thommen, VH Koelzer, P Herzig, A Roller, M Trefny, S Dimeloe, ...
Nature medicine 24 (7), 994-1004, 2018
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
W Schaefer, JT Regula, M Bähner, J Schanzer, R Croasdale, H Dürr, ...
Proceedings of the National academy of Sciences 108 (27), 11187-11192, 2011
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling
M Felcht, R Luck, A Schering, P Seidel, K Srivastava, J Hu, A Bartol, ...
The Journal of clinical investigation 122 (6), 1991-2005, 2012
Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53
R Stoll, C Renner, S Hansen, S Palme, C Klein, A Belling, W Zeslawski, ...
Biochemistry 40 (2), 336-344, 2001
p53 contains large unstructured regions in its native state
S Bell, C Klein, L Müller, S Hansen, J Buchner
Journal of molecular biology 322 (5), 917-927, 2002
Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors
DS Thommen, J Schreiner, P Müller, P Herzig, A Roller, A Belousov, ...
Cancer immunology research 3 (12), 1344-1355, 2015
Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
S Herter, F Herting, O Mundigl, I Waldhauer, T Weinzierl, T Fauti, G Muth, ...
Molecular cancer therapeutics 12 (10), 2031-2042, 2013
Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
C Klein, A Lammens, W Schäfer, G Georges, M Schwaiger, E Mössner, ...
MAbs 5 (1), 22-33, 2013
A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors
M Bacac, T Fauti, J Sam, S Colombetti, T Weinzierl, D Ouaret, W Bodmer, ...
Clinical Cancer Research 22 (13), 3286-3297, 2016
Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
T Schlothauer, S Herter, CF Koller, S Grau-Richards, V Steinhart, C Spick, ...
Protein Engineering, Design and Selection 29 (10), 457-466, 2016
WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization
Y Tomita, N Marchenko, S Erster, A Nemajerova, A Dehner, C Klein, ...
Journal of Biological Chemistry 281 (13), 8600-8606, 2006
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
G Niederfellner, A Lammens, O Mundigl, GJ Georges, W Schaefer, ...
Blood, The Journal of the American Society of Hematology 118 (2), 358-367, 2011
Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment
A Seckinger, JA Delgado, S Moser, L Moreno, B Neuber, A Grab, S Lipp, ...
Cancer cell 31 (3), 396-410, 2017
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
M Mayoux, A Roller, V Pulko, S Sammicheli, S Chen, E Sum, C Jost, ...
Science translational medicine 12 (534), eaav7431, 2020
The N-terminal domain of p53 is natively unfolded
R Dawson, L Müller, A Dehner, C Klein, H Kessler, J Buchner
Journal of molecular biology 332 (5), 1131-1141, 2003
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab
J Golay, F Da Roit, L Bologna, C Ferrara, JH Leusen, A Rambaldi, C Klein, ...
Blood, The Journal of the American Society of Hematology 122 (20), 3482-3491, 2013
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies
C Klein, C Sustmann, M Thomas, K Stubenrauch, R Croasdale, ...
MAbs 4 (6), 653-663, 2012
Targeting the p53–MDM2 interaction to treat cancer
C Klein, LT Vassilev
British journal of cancer 91 (8), 1415-1419, 2004
The system can't perform the operation now. Try again later.
Articles 1–20